Blog
Commercialisation

Your technology isn't finished yet.
Here's what you can sell right now.

Pierre Bauër · 8 min read · Deeptech Partners

"Our technology isn't ready yet." It's the sentence I hear most often from deeptech founders — and in the vast majority of cases, it's a belief that costs them dearly.

It starts from a valid intuition: you don't yet have a commercial product, no stable version ready to be sold at scale. But it rests on a fundamental confusion between the final product and what you already have that is valuable. These are two very different things.

The truth is that from the moment you have a differentiated technology — even at TRL 3 or 4 — you very likely have assets that industrial players are willing to pay for. Not for a finished product. But for something else.

The perfection trap

The deeptech world is shaped by years of scientific training that values rigour, validation, and certainty. You publish when results are robust. You present when the data is solid. You commercialise when the product is ready.

This logic is perfectly adapted to science. In business, it is disastrous.

While you wait for your technology to be perfect, you're missing something crucial: the conversation with the market. These early exchanges will tell you whether your vision of the final product actually matches a real industrial need — or whether you'll spend three years developing something no one wants in the form you're imagining.

Early commercialisation is not a concession on quality. It is a tool for validating the direction of your R&D.

What you can sell today

Here are four asset categories that most deeptech startups underestimate or ignore entirely.

1. Expertise and technical services

Your team has accumulated rare expertise — on a material, a process, an analytical method. This expertise has immediate market value for industrial players who lack the resources or time to develop it in-house.

Concretely, this can take the form of feasibility studies, technical audits, consulting on a specific application, or analysis of samples sent by potential partners. These engagements are often short (a few weeks), well remunerated (€10,000 to €80,000), and have a significant strategic advantage: they place you inside an industrial organisation. You learn its constraints, its processes, its decision criteria.

2. Access to unique equipment or data

If your laboratory has characterisation, synthesis, or analysis equipment that exists nowhere else — or that few players can operate — that is a commercial asset. Pharmaceutical companies, chemists, and equipment manufacturers regularly need access to capabilities they don't possess.

Similarly, if your R&D has generated rare proprietary data (molecular databases, test results on specific materials, in vivo performance data), this data has value in itself for players seeking to accelerate their own development.

3. Contract R&D and co-development

You can offer industrial players the opportunity to solve, using your methods and your technology-in-development, a specific technical problem they have identified. You are not selling your product — they are funding part of your R&D in exchange for a result useful to their business.

This model is particularly powerful: it funds your development, validates the industrial application of your technology, and creates a contractual link with a company that may become your first real customer or partner.

4. Partial licensing or early access to your IP

Even if your technology isn't complete, you may have already filed patents on certain aspects, applications, or processes. These rights can be licensed in a targeted way — for a specific application, in a particular geographic territory, or for a precise use — without mortgaging your overall development freedom.

Option agreements can also work at this stage: a company pays to reserve the right to license or acquire your technology under certain future conditions. You generate cash now, without committing to a final price you can't yet accurately estimate.

How to identify what applies to your situation

These four categories don't all apply to every startup. To identify yours, ask yourself two simple questions.

First question: what can we do or measure that no one else can do? Not what you'll know how to do in two years — what you already do. List it factually, without filter.

Second question: who in industry would need this capability — even imperfectly — to solve a problem they have right now? Not in two years. Right now.

The answers will give you a first list of targets and possible offerings. It's not a complete commercial plan, but it's the starting point of a conversation — and that's all you need to begin.

Early commercialisation doesn't compromise your development. It guides it. Founders who engage these conversations early arrive at the final commercial stage with a market understanding their competitors simply don't have.

The question is not "is my product ready?" The question is: "what do I already have that has value for someone else?"

The answer, almost always, is: more than you think.

Want to identify what you can commercialise right now?

A 45-minute conversation to assess your situation and explore together what is already valuable in your technology.

Get in touch